FluoGuide announces head and neck cancer therapy results pharmatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmatimes.com Daily Mail and Mail on Sunday newspapers.
Copenhagen, Denmark, 6 November 2022 - FluoGuide A/S is pleased to announce that FG001 lights up in 5 out of 7 patients in an interim evaluation in the ongoing phase IIa trial in non-small cell lung. | November 6, 2022
FluoGuide has completed a directed share issue raising SEK 75 million
Copenhagen, Denmark,
12 May 2021 – FluoGuide A/S (publ a developer of surgical precision solutions within oncology (“FluoGuide” or the “Company”) (Nasdaq First North Growth Market: FLUO) hereby announces that the Company has successfully completed a directed share issue raising SEK 75 million in gross proceeds (the “Directed Share Issue”).
Fluoguide
Publicerad: 12 maj 2021, 07:44
The board of directors of FluoGuide has, based on the authorization to increase the share capital in the Company’s articles of association section 3.2.3 granted by the annual general meeting on 9 February 2021, and as indicated in the Company’s press release yesterday, resolved to increase the share capital without pre-emptive subscription rights for the Company’s existing shareholders with nominal DKK 78,947.4 corresponding to 789,474 new shares of nominal DKK 0.1 each at a subscription price of SEK 95 per sha
Nasdaq Nordic: Nasdaq Stockholm Welcomes FluoGuide to the Nasdaq First North Growth Market
Stockholm, February 24, 2020 - Nasdaq (Nasdaq: NDAQ) announces that trading in
FluoGuide A/S shares (short name FLUO) commences today on Nasdaq First North
Growth Market. The company belongs to the Health care sector. FluoGuide is the
12th company to be admitted to trading on Nasdaq s Nordic markets in 2021.
FluoGuide develops surgical solutions that are expected to reduce suffering for
cancer patients and increase the likelihood of cure as well as reducing costs
for the health care system. Intelligent surgical targeting has a potential to
help surgeons reduce costs and time for any kind of surgery. Surgical targeting